SCI时时刷

search
+
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome
Eculizumab, a humanized monoclonal antibody targeting complement C5, is the first approved drug for complement-mediated di...
Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back
Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back
Immunotherapy with checkpoint inhibitors has become the cornerstone of systemic treatment for non-oncogene addicted non-sm...
Use of Semaglutide (Wegovy) in Adults in France: A Nationwide Drug Utilization Study
Use of Semaglutide (Wegovy) in Adults in France: A Nationwide Drug Utilization Study
Glucagon-like peptide 1 receptor agonists have shown promising results in obesity treatment. In France, semaglutide 2.4-mg...
Islet Cell Replacement and Regeneration for Type 1 Diabetes: Current Developments and Future Prospects
Islet Cell Replacement and Regeneration for Type 1 Diabetes: Current Developments and Future Prospects
Type 1 diabetes (T1D) is a chronic autoimmune disorder characterized by the destruction of insulin-producing beta cells in...
TL1A Inhibition in Inflammatory Bowel Disease: A Pipeline Review
TL1A Inhibition in Inflammatory Bowel Disease: A Pipeline Review
Inflammatory bowel disease (IBD), encompassing Crohn’s disease (CD) and ulcerative colitis (UC), remains challenging...
Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network
Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network
Psoriatic arthritis (PsA) is a common comorbidity in patients with psoriasis (PsO) that leads to significant disease burde...
An Automated Tool for Glycosimilarity Assessment of mAb Therapeutic Biosimilars: Trastuzumab and Bevacizumab as Case Studies
An Automated Tool for Glycosimilarity Assessment of mAb Therapeutic Biosimilars: Trastuzumab and Bevacizumab as Case Studies
With the expiration of patents for multiple biotherapeutics, biosimilars are gaining traction globally as cost-effective a...
New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making
New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making
Myasthenia gravis (MG) is a rare autoimmune disease characterised by exertion-induced muscle weakness that can lead to pot...
State-of-the-Art Liver Cancer Organoids: Modeling Cancer Stem Cell Heterogeneity for Personalized Treatment
State-of-the-Art Liver Cancer Organoids: Modeling Cancer Stem Cell Heterogeneity for Personalized Treatment
Liver cancer poses a global health challenge with limited therapeutic options. Notably, the limited success of current the...
CAR T-Cell Therapy for Rheumatic Diseases: What Does the Future Hold?
CAR T-Cell Therapy for Rheumatic Diseases: What Does the Future Hold?
Chimeric antigen receptor (CAR) T-cell therapy, initially successful in treating hematological malignancies, is emerging a...
Sequelae of B-Cell Depleting Therapy: An Immunologist’s Perspective
Sequelae of B-Cell Depleting Therapy: An Immunologist’s Perspective
B-cell depleting therapy (BCDT) has revolutionised the treatment of B-cell malignancies and autoimmune diseases by targeti...
The Evolving Applications of Bispecific Antibodies: Reaping the Harvest of Early Sowing and Planting New Seeds
The Evolving Applications of Bispecific Antibodies: Reaping the Harvest of Early Sowing and Planting New Seeds
After decades of gradual progress from conceptualization to early clinical trials (1960–2000), the therapeutic poten...
Investigational RNA Interference Agents for Hepatitis B
Investigational RNA Interference Agents for Hepatitis B
Functional cure of chronic hepatitis B (CHB)—defined as sustained seroclearance of hepatitis B surface antigen (HBsA...
Relevance of Neutralizing Antibodies for the Pharmacokinetics of Pegunigalsidase Alfa in Patients with Fabry Disease
Relevance of Neutralizing Antibodies for the Pharmacokinetics of Pegunigalsidase Alfa in Patients with Fabry Disease
Pegunigalsidase alfa is a newly approved drug for the treatment of Fabry disease, designed to increase the plasma half-lif...
Accelerating CAR-T Cell Therapies with Small-Molecule Inhibitors
Accelerating CAR-T Cell Therapies with Small-Molecule Inhibitors
Chimeric antigen receptor T-cell therapies have markedly improved the survival rates of patients with B-cell malignancies....
Effect of Biological Therapy for Psoriasis on the Development of Psoriatic Arthritis: A Population-Based Cohort Study
Effect of Biological Therapy for Psoriasis on the Development of Psoriatic Arthritis: A Population-Based Cohort Study
Evidence comparing the impact of various biologics for psoriasis on the progression to psoriatic arthritis (PsA) is limite...
Discovery of Therapeutic Antibodies Targeting Complex Multi-Spanning Membrane Proteins
Discovery of Therapeutic Antibodies Targeting Complex Multi-Spanning Membrane Proteins
Complex integral membrane proteins, which are embedded in the cell surface lipid bilayer by multiple transmembrane spannin...
Eblasakimab, an Anti-IL‑13Rα1 Antibody, Reduces Atopy-Associated Serum Biomarkers in Moderate‑to‑Severe Atopic Dermatitis
Eblasakimab, an Anti-IL‑13Rα1 Antibody, Reduces Atopy-Associated Serum Biomarkers in Moderate‑to‑Severe Atopic Dermatitis
Eblasakimab, a first-in-class monoclonal antibody with a unique mechanism to target the interleukin (IL)-13 receptor alpha...
Advanced Therapy Medicinal Products: Availability, Access and Expenditure in Italy
Advanced Therapy Medicinal Products: Availability, Access and Expenditure in Italy
Advanced therapy medicinal products (ATMPs) are an innovative output of biomedical research, characterized by a high level...
Real-World Comparative Analysis of Trastuzumab Originator and Biosimilars: Safety, Efficacy, and Cost Effectiveness
Real-World Comparative Analysis of Trastuzumab Originator and Biosimilars: Safety, Efficacy, and Cost Effectiveness
Despite the global use of trastuzumab biosimilars, concerns remain regarding their efficacy and safety. In particular, whe...
Adverse Impacts of PEGylated Protein Therapeutics: A Targeted Literature Review
Adverse Impacts of PEGylated Protein Therapeutics: A Targeted Literature Review
The beneficial effects of polyethylene glycol (PEG)-conjugated therapeutics, such as increased half-life, solubility, stab...
Patient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER Study
Patient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER Study
Biosimilars are cost-effective alternatives to reference products for patients with inflammatory bowel diseases (IBD) and ...
Biochemical Amenability in Fabry Patients Under Chaperone Therapy—How and When to Test?
Biochemical Amenability in Fabry Patients Under Chaperone Therapy—How and When to Test?
Current recommendations for Fabry disease include α-galactosidase A (AGAL) activity measurements to assess the bioche...
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab
A biosimilar medicine is a successor to a reference (‘originator’/’original-brand’) biologic medic...
Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects
Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects
Nivolumab (Opdivo®) is the first anti-PD-1 antibody approved in the world. LY01015 is a potential biosimilar of nivol...
Chikungunya Virus Vaccines: A Review of IXCHIQ and PXVX0317 from Pre-Clinical Evaluation to Licensure
Chikungunya Virus Vaccines: A Review of IXCHIQ and PXVX0317 from Pre-Clinical Evaluation to Licensure
Chikungunya virus is an emerging mosquito-borne alphavirus that causes febrile illness and arthritic disease. Chikungunya ...
Pulmonary Arterial Hypertension and TGF-β Superfamily Signaling: Focus on Sotatercept
Pulmonary Arterial Hypertension and TGF-β Superfamily Signaling: Focus on Sotatercept
Pulmonary arterial hypertension (PAH) is a rare and progressive disease that continues to remain highly morbid despite mul...
Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study
Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study
The optimal infliximab dose intensification strategy to address loss of response associated with subtherapeutic i...
Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond
Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond
Mucopolysaccharidosis type II (MPS II) is a rare, pediatric, neurometabolic disorder due to the lack of activity of the ly...
Systematic Review of Genetic Substrate Reduction Therapy in Lysosomal Storage Diseases: Opportunities, Challenges and Delivery Systems
Systematic Review of Genetic Substrate Reduction Therapy in Lysosomal Storage Diseases: Opportunities, Challenges and Delivery Systems
Genetic substrate reduction therapy (gSRT), which involves the use of nucleic acids to downregulate the genes involved in ...
阅读更多
format_indent_increase